Poynten I Mary, Tabrizi Sepehr N, Jin Fengyi, Templeton David J, Machalek Dorothy A, Cornall Alyssa, Phillips Samuel, Fairley Christopher K, Garland Suzanne M, Law Carmella, Carr Andrew, Hillman Richard J, Grulich Andrew E
The Kirby Institute, University of New South Wales, Sydney, Australia.
Regional HPV LabNet Reference Laboratory, Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, Victoria, Australia; Department of Obstetrics and Gynecology, University of Melbourne, Victoria, Australia; Murdoch Children's Research Institute, Parkville, Victoria, Australia.
Papillomavirus Res. 2017 Jun;3:80-84. doi: 10.1016/j.pvr.2017.02.003. Epub 2017 Feb 21.
HPV causes ~90% of anal cancer and HPV16 is the type most commonly associated with anal cancer. Gay and bisexual men (GBM) are at greatly increased risk. We investigated patterns of vaccine-preventable anal HPV in older GBM.
The Study of the Prevention of Anal Cancer (SPANC) is an ongoing, prospective cohort study of HIV-positive and HIV-negative Australian GBM. Participants completed questionnaires and underwent an anal swab for HPV genotyping using Roche Linear Array. We analysed baseline data from SPANC by HPV type, mean number of types, stratified by age and HIV status.
Anal HPV results from 606 (98.2%) of 617 participants (median age 49 years, 35.7% HIV-positive) showed 525 (86.7%) had ≥1 HPV type and 178 (29.4%) had HPV16. Over one third of participants (214, 35.3%) had no nonavalent vaccine-preventable types detected. Two (0.3%) participants had all quadrivalent types and none had all nonavalent vaccine types. HIV-positive participants (p<0.001) and younger participants (p=0.059) were more likely to have more vaccine-preventable HPV types detected.
Anal HPV was highly prevalent in this largely community-based GBM cohort. Vaccine-preventable HPV16 was detected in approximately one third of participants. These findings suggest that the potential efficacy of HPV vaccination of older GBM should be explored.
人乳头瘤病毒（HPV）导致约90%的肛管癌，其中HPV16是与肛管癌最常相关的类型。男同性恋者和双性恋男性（GBM）的患病风险大幅增加。我们调查了老年GBM中可通过疫苗预防的肛管HPV模式。
肛管癌预防研究（SPANC）是一项正在进行的针对澳大利亚HIV阳性和HIV阴性GBM的前瞻性队列研究。参与者完成问卷调查，并接受使用罗氏线性阵列进行HPV基因分型的肛管拭子检查。我们按HPV类型、类型平均数对SPANC的基线数据进行分析，并按年龄和HIV状态分层。
617名参与者中606名（98.2%）（中位年龄49岁，35.7%为HIV阳性）的肛管HPV检测结果显示，525名（86.7%）有≥1种HPV类型，178名（29.4%）有HPV16。超过三分之一的参与者（214名，35.3%）未检测到九价疫苗可预防的类型。2名（0.3%）参与者有所有四价疫苗类型，无人有所有九价疫苗类型。HIV阳性参与者（p<0.001）和年轻参与者（p=0.059）更有可能检测到更多可通过疫苗预防的HPV类型。
在这个以社区为主的GBM队列中，肛管HPV非常普遍。约三分之一的参与者检测到可通过疫苗预防的HPV16。这些发现表明应探索对老年GBM进行HPV疫苗接种的潜在效果。
